143 related articles for article (PubMed ID: 21727930)
1. Chemotherapy: Metastatic pancreatic cancer--is FOLFIRINOX the new standard?
Saif MW; Chabot J
Nat Rev Clin Oncol; 2011 Jul; 8(8):452-3. PubMed ID: 21727930
[No Abstract] [Full Text] [Related]
2. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Vaccaro V; Sperduti I; Milella M
N Engl J Med; 2011 Aug; 365(8):768-9; author reply 769. PubMed ID: 21864184
[No Abstract] [Full Text] [Related]
3. FOLFIRINOX: a small step or a great leap forward?
Ko AH
J Clin Oncol; 2011 Oct; 29(28):3727-9. PubMed ID: 21900100
[No Abstract] [Full Text] [Related]
4. The role of the FOLFIRINOX regimen for advanced pancreatic cancer.
Conroy T; Gavoille C; Samalin E; Ychou M; Ducreux M
Curr Oncol Rep; 2013 Apr; 15(2):182-9. PubMed ID: 23341367
[TBL] [Abstract][Full Text] [Related]
5. Influcence of localization of primary tumor on effectiveness of 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) in patients with metastatic pancreatic adenocarcinoma: a retrospective study.
Lorgis V; Chauffert B; Gentil J; Ghiringhelli F
Anticancer Res; 2012 Sep; 32(9):4125-30. PubMed ID: 22993372
[TBL] [Abstract][Full Text] [Related]
6. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma.
Wagner M; Antunes C; Pietrasz D; Cassinotto C; Zappa M; Sa Cunha A; Lucidarme O; Bachet JB
Eur Radiol; 2017 Jul; 27(7):3104-3116. PubMed ID: 27896469
[TBL] [Abstract][Full Text] [Related]
7. FOLFIRINOX in locally advanced pancreas adenocarcinoma: back to the future?
Bekaii-Saab T; Goldberg RM
Oncologist; 2013; 18(5):487-9. PubMed ID: 23704222
[No Abstract] [Full Text] [Related]
8. FOLFIRINOX: a new standard treatment for advanced pancreatic cancer?
Kim R
Lancet Oncol; 2011 Jan; 12(1):8-9. PubMed ID: 21050812
[No Abstract] [Full Text] [Related]
9. Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial.
Alistar A; Morris BB; Desnoyer R; Klepin HD; Hosseinzadeh K; Clark C; Cameron A; Leyendecker J; D'Agostino R; Topaloglu U; Boteju LW; Boteju AR; Shorr R; Zachar Z; Bingham PM; Ahmed T; Crane S; Shah R; Migliano JJ; Pardee TS; Miller L; Hawkins G; Jin G; Zhang W; Pasche B
Lancet Oncol; 2017 Jun; 18(6):770-778. PubMed ID: 28495639
[TBL] [Abstract][Full Text] [Related]
10. FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience.
Faris JE; Blaszkowsky LS; McDermott S; Guimaraes AR; Szymonifka J; Huynh MA; Ferrone CR; Wargo JA; Allen JN; Dias LE; Kwak EL; Lillemoe KD; Thayer SP; Murphy JE; Zhu AX; Sahani DV; Wo JY; Clark JW; Fernandez-del Castillo C; Ryan DP; Hong TS
Oncologist; 2013; 18(5):543-8. PubMed ID: 23657686
[TBL] [Abstract][Full Text] [Related]
11. Treatment of High-Grade Metastatic Pancreatic Neuroendocrine Carcinoma with FOLFIRINOX.
Zhu J; Strosberg JR; Dropkin E; Strickler JH
J Gastrointest Cancer; 2015 Jun; 46(2):166-9. PubMed ID: 25662891
[No Abstract] [Full Text] [Related]
12. Irinotecan or oxaliplatin for first-line treatment of advanced colorectal cancer?
Punt CJ
Ann Oncol; 2005 Jun; 16(6):845-6. PubMed ID: 15890668
[No Abstract] [Full Text] [Related]
13. A R0 resection case of initially unresectable metastatic pancreatic cancer downstaged by FOLFIRINOX therapy.
Sasaki T; Isayama H; Aoki T; Tanaka M; Hamada T; Nakai Y; Sakamoto Y; Hasegawa K; Morikawa T; Fukayama M; Kokudo N; Koike K
Pancreas; 2014 Aug; 43(6):972-4. PubMed ID: 25010709
[No Abstract] [Full Text] [Related]
14. FOLFIRINOX - a new paradigm in the treatment of pancreatic cancer.
Papadatos-Pastos D; Thillai K; Rabbie R; Ross P; Sarker D
Expert Rev Anticancer Ther; 2014 Oct; 14(10):1115-25. PubMed ID: 25204327
[TBL] [Abstract][Full Text] [Related]
15. Unresectable locally advanced pancreatic cancer: treatment with neoadjuvant leucovorin, fluorouracil, irinotecan, and oxaliplatin and assessment of surgical resectability.
Mondo EL; Noel MS; Katz AW; Schoeniger LO; Hezel AF
J Clin Oncol; 2013 Jan; 31(3):e37-9. PubMed ID: 23233707
[No Abstract] [Full Text] [Related]
16. FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity.
Gunturu KS; Yao X; Cong X; Thumar JR; Hochster HS; Stein SM; Lacy J
Med Oncol; 2013 Mar; 30(1):361. PubMed ID: 23271209
[TBL] [Abstract][Full Text] [Related]
17. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer.
Ferrone CR; Marchegiani G; Hong TS; Ryan DP; Deshpande V; McDonnell EI; Sabbatino F; Santos DD; Allen JN; Blaszkowsky LS; Clark JW; Faris JE; Goyal L; Kwak EL; Murphy JE; Ting DT; Wo JY; Zhu AX; Warshaw AL; Lillemoe KD; Fernández-del Castillo C
Ann Surg; 2015 Jan; 261(1):12-7. PubMed ID: 25599322
[TBL] [Abstract][Full Text] [Related]
18. Metastatic Pancreatic Carcinoma and Experience with FOLFIRINOX - a Cross Sectional Analysis From a Developing Country.
Zahir MN; Jabbar AA
Asian Pac J Cancer Prev; 2015; 16(14):6001-6. PubMed ID: 26320487
[TBL] [Abstract][Full Text] [Related]
19. [Standard chemotherapy for colonic neoplasms].
Hyodo I
Nihon Naika Gakkai Zasshi; 2007 Feb; 96(2):283-8. PubMed ID: 17370594
[No Abstract] [Full Text] [Related]
20. A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma.
Ko AH; LoConte N; Tempero MA; Walker EJ; Kate Kelley R; Lewis S; Chang WC; Kantoff E; Vannier MW; Catenacci DV; Venook AP; Kindler HL
Pancreas; 2016 Mar; 45(3):370-5. PubMed ID: 26390428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]